Tempus Sculptor Study: Small Cell Lung Cancer (SCLC) Observational Study

Inclusion Criteria:

Histologically confirmed small cell lung cancer diagnosis
Diagnosis made with excisional or core needle biopsy specimen (fine needle aspirate may be permitted with approval from the PI)
Subjects must submit fresh or archived FFPE tumor sample to the central laboratory
ECOG performance status of 0 or 1 at time of enrollment
Planned extensive stage first-line therapy of etoposide plus carboplatin plus PD-L1 inhibitor (atezolizumab or durvalumab)
Extensive stage disease at time of diagnosis
Willing and able to provide informed consent

Exclusion Criteria:

History of prior systemic treatment of SCLC
History of radiotherapy or planned radiotherapy to all measurable disease foci
Prior diagnosis of non-small cell lung cancer
Mixed small cell and non-small cell histology
Suspected metastatic cancer from other sites (i.e., those without a known or suspected lung primary diagnosis)
Not willing to have additional blood samples collected